Shares of CVRx, Inc. (NASDAQ:CVRX – Get Free Report) have received a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $3.30.
CVRX has been the topic of several recent research reports. Craig Hallum cut shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a report on Friday, October 30th. Canaccord Genuity Group lowered CVRx from a “buy” rating to a “hold” rating and dropped their price target for the stock from $5.00 to $2.00 in a research report on Friday, November 6th. Wall Street Zen cut CVRx from a “sell” rating to a “strong sell” rating in a research note on Sunday. Finally, Piper Sandler cut CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research note on Friday, August 7th.
View Our Latest Research Report on CVRx
Recent CVRx Headlines
Here are a few of the latest headlines about CVRX:
- Negative Sentiment: Investors allege CVRx misled shareholders during July 25, 2023–August 6, 2026, including about alleged conduct that could expose the company to liability under the False Claims Act and Anti-Kickback Statute. The complaints cite a DOJ Civil Investigative Demand, sharp revenue-guidance reductions, disruption to the commercial sales force, and the departure of the chief revenue officer. These remain allegations, not proven findings; continued litigation could bring costs and uncertainty. Securities fraud lawsuit report Hagens Berman class-action notice
- Neutral Sentiment: Law firms are publicizing the case and urging eligible investors to seek appointment as lead plaintiff by January 8, 2027. These repeated notices largely concern the same lawsuit rather than separate new cases or company operating updates. Lead plaintiff deadline notice
Hedge Funds Weigh In On CVRx
Institutional investors and hedge funds have recently modified their holdings of the stock. Johnson & Johnson bought a new position in shares of CVRx during the 2nd quarter valued at approximately $20,687,786. BlackRock Inc. bought a new stake in CVRx in the second quarter worth $6,402,000. Royal Bank of Canada lifted its position in CVRx by 6,559.3% in the first quarter. Royal Bank of Canada now owns 706,950 shares of the company’s stock worth $6,688,000 after buying an additional 696,334 shares during the last quarter. FourWorld Capital Management LLC lifted its position in CVRx by 28.9% in the first quarter. FourWorld Capital Management LLC now owns 231,996 shares of the company’s stock worth $2,195,000 after buying an additional 51,996 shares during the last quarter. Finally, First Eagle Investment Management LLC purchased a new position in CVRx during the third quarter worth $386,000. Hedge funds and other institutional investors own 75.27% of the company’s stock.
CVRx Price Performance
CVRx stock traded down $0.02 during mid-day trading on Friday, reaching $0.61. 759,885 shares of the company’s stock traded hands, compared to its average volume of 800,013. The company has a market cap of $17.30 million, a price-to-earnings ratio of -0.30 and a beta of 0.81. The stock has a 50 day moving average of $1.85 and a two-hundred day moving average of $5.00. The company has a quick ratio of 5.71, a current ratio of 6.80 and a debt-to-equity ratio of 4.24. CVRx has a 12-month low of $0.60 and a 12-month high of $10.28.
CVRx (NASDAQ:CVRX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.02). CVRx had a negative net margin of 88.28% and a negative return on equity of 208.45%. The business had revenue of $13.83 million for the quarter, compared to the consensus estimate of $13.93 million. Equities analysts forecast that CVRx will post -2.04 earnings per share for the current year.
About CVRx
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
Further Reading
- Five stocks we like better than CVRx
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
